● TIER 3 — Information onlyGRADE B (ostarine/LGD) / D (RAD-140)SARMs
SARMs (ostarine, LGD-4033, RAD-140)
Selective androgen receptor modulators. Research verification: Yes (TGA pending). 4 human study record(s) in the FitClinicMD studies database.
GOALS · Muscle / body composition
FDA status
None approved; FDA warns against SARMs in supplements.
Compounding (503A/503B)
Not compoundable.
DEA
Not federally scheduled (as far as found).
WADA (sport)
S1.2 Other anabolic agents (incl. SARMs)
Mechanism
Tissue-selective AR agonists.
Human evidence · 4
RAD-140 drug-induced liver injury case. Idiosyncratic drug-induced liver injury related to use of novel selective androgen receptor modulator RAD140 (Testalone): a case report.
JAMA 2017: of 44 'SARM' products, only 52% contained SARMs. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet.
Enobosarm phase 2 cancer cachexia, n=159. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.
LGD-4033 phase 1, n=76 young men. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.
Reference only. This page summarizes publicly available regulatory and research information about SARMs (ostarine, LGD-4033, RAD-140). It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.